2024
Emerging therapeutic options for follicular-derived thyroid cancer in the era of immunotherapy
Turner N, Hamidi S, Ouni R, Rico R, Henderson Y, Puche M, Alekseev S, Colunga-Minutti J, Zafereo M, Lai S, Kim S, Cabanillas M, Nurieva R. Emerging therapeutic options for follicular-derived thyroid cancer in the era of immunotherapy. Frontiers In Immunology 2024, 15: 1369780. PMID: 38868771, PMCID: PMC11167082, DOI: 10.3389/fimmu.2024.1369780.Peer-Reviewed Original ResearchConceptsAnaplastic thyroid cancerFollicular-derived thyroid cancersAdvanced thyroid cancerThyroid cancerFood and Drug AdministrationManagement of advanced thyroid cancerEra of immunotherapyTargeted kinase inhibitorsU.S Food and Drug AdministrationImmune milieuRefractory diseaseExcellent prognosisTherapeutic optionsTreatment optionsKinase inhibitorsDrug AdministrationGenetic driversTherapeutic avenuesCancerImmunotherapyGenetic landscapeRadioiodineTreatmentMolecular basisOptions
2021
Erratum: Rodriguez et al. Substance P Antagonism as a Novel Therapeutic Option to Enhance Efficacy of Cisplatin in Triple Negative Breast Cancer and Protect PC12 Cells against Cisplatin-Induced Oxidative Stress and Apoptosis. Cancers 2021, 13, 3871
Rodriguez E, Pei G, Zhao Z, Kim S, German A, Robinson P. Erratum: Rodriguez et al. Substance P Antagonism as a Novel Therapeutic Option to Enhance Efficacy of Cisplatin in Triple Negative Breast Cancer and Protect PC12 Cells against Cisplatin-Induced Oxidative Stress and Apoptosis. Cancers 2021, 13, 3871. Cancers 2021, 13: 5178. PMID: 34680400, PMCID: PMC8533910, DOI: 10.3390/cancers13205178.Peer-Reviewed Original ResearchSubstance P Antagonism as a Novel Therapeutic Option to Enhance Efficacy of Cisplatin in Triple Negative Breast Cancer and Protect PC12 Cells against Cisplatin-Induced Oxidative Stress and Apoptosis
Rodriguez E, Pei G, Zhao Z, Kim S, German A, Robinson P. Substance P Antagonism as a Novel Therapeutic Option to Enhance Efficacy of Cisplatin in Triple Negative Breast Cancer and Protect PC12 Cells against Cisplatin-Induced Oxidative Stress and Apoptosis. Cancers 2021, 13: 3871. PMID: 34359773, PMCID: PMC8345440, DOI: 10.3390/cancers13153871.Peer-Reviewed Original ResearchTriple-negative breast cancerSP-receptor antagonismTriple-negative breast cancer cell linesTherapeutic optionsBreast cancerSP receptorsCell linesFlow cytometryTriple negative breast cancerCisplatin-induced oxidative stressTriple-negative breast cancer cellsSubstance P antagonismEfficacy of cisplatinGenes associated with metastasisNegative breast cancerHigh-affinity SP receptorResponse to cisplatinCisplatin-inducedNeuronal cell lineTreatment strategiesProduction of reactive oxygen speciesCisplatinPC12 cellsCell cycle progressionReactive oxygen species